U.S. FDA approval and launch of Sugammadex Injection

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹2420.00

prior close

₹2409.30

announcement price

In-mkt

timing

Nifty Midcap 150market+0.5%-0.7% vs market

Pharmaceuticals peers, median of 164sector+0.1%-0.4% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.5

15m

+0.4

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3+0.5-0.7+0.1-0.4

Next day

-1.1+1.7-2.8+1.1-2.2

-1.7+1.4-3.1+1.0-2.7

-1.5+1.6-3.1+1.1-2.6

-1.4+1.2-2.7+1.2-2.7

-2.0+1.4-3.5+1.5-3.5

-5.8+1.9-7.7+2.3-8.1

15d

-9.0+1.6-10.7+1.3-10.4

-9.6+2.2-11.8+2.3-11.9

-16.1-5.1-11.1+3.2-19.3

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin received U.S. FDA approval for its Abbreviated New Drug Application and launched Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL single-dose vials) in the United States. It is the bioequivalent of Merck's Bridion Injection and is used to reverse neuromuscular blockade in adults and pediatric patients aged 2 and older undergoing surgery.

Likely market impact

Positive — new generic product launch in the key U.S. market, expected to add to U.S. revenues and strengthen Lupin's complex generics portfolio.